Related Experiment Video
Updated: Mar 9, 2026
10:33
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
Published on: December 17, 2021
3.3K
Mycophenolate mofetil as an immunomodulator in refractory noninfectious uveitis
Ever Ernesto Caso Rodriguez1, Viviane Mayumi Sakata1, Daniel Cesar Torres Melo Cavalcanti1
1Clínica Oftalmológica, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
Arquivos Brasileiros De Oftalmologia
|January 12, 2017
Summary
Mycophenolate mofetil (MMF) effectively treats noninfectious uveitis, reducing inflammation and prednisone dosage in most patients. While generally well-tolerated, potential side effects require monitoring for optimal ocular inflammation management.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Noninfectious uveitis is a chronic inflammatory eye condition requiring effective immunosuppressive therapy.
- Standardization of Uveitis Nomenclature (SUN) Working Group guidelines aid in evaluating treatment outcomes.
- Mycophenolate mofetil (MMF) is an immunosuppressant used for various autoimmune conditions.
Purpose of the Study:
- To assess the efficacy and tolerance of mycophenolate mofetil (MMF) in treating noninfectious uveitis.
- To compare MMF's effectiveness with other immunosuppressive treatments for ocular inflammation.
- To evaluate outcomes using Standardization of Uveitis Nomenclature (SUN) Working Group criteria.
Main Methods:
- Retrospective case series of 16 patients with refractory noninfectious uveitis treated with MMF for at least 6 months.
- Patients were evaluated at 6, 12, and 24 months after achieving optimal MMF dosage (mean 2.2 g/day).
- Outcomes included prednisone dosage reduction (≤10 mg/day), inflammation control, and adverse events.
Main Results:
- 67% of patients achieved reduced prednisone dosage by 1 year, and 83% by 2 years.
- Complete or partial inflammation control was observed in 43.7% of patients at 12 months.
- Adverse effects like gastrointestinal issues and infections occurred at a low rate (0.03 per patient-year).
Conclusions:
- MMF demonstrates significant efficacy in managing noninfectious uveitis, aligning with existing literature.
- The drug exhibits moderate tolerability, with adverse events being infrequent.
- Extended patient observation (≥1 year) is recommended for a comprehensive understanding of MMF's long-term efficacy in ocular inflammation.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
621
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
621
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
588
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
588
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
580
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
580